MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41375-021-01444-6

Медицинская библиотека · Leukemia · 2021

Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma.

Newman Alexander M, Zaka Masood, Zhou Peixun, Blain Alex E, Erhorn Amy, Barnard Amy, Crossland Rachel E, Wilkinson Sarah, Enshaei Amir, De Zordi Julian, Harding Fiona, Taj Mary, Wood Katrina M, Televantou Despina, Turner Suzanne D, Burke G A Amos, Harrison Christine J, Bomken Simon, Bacon Chris M, Rand Vikki

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Children with B-cell non-Hodgkin lymphoma (B-NHL) have an excellent chance of survival, however, current clinical risk stratification places as many as half of patients in a high-risk group receiving very intensive chemo-immunotherapy. TP53 alterations are associated with adverse outcome in many malignancies; however, whilst common in paediatric B-NHL, their utility as a risk classifier is unknown. We evaluated the clinical significance of TP53 abnormalities (mutations, deletion and/or copy number neutral loss of heterozygosity) in a large UK paediatric B-NHL cohort and determined their impact on survival. TP53 abnormalities were present in 54.7% of cases and were independently associated with a significantly inferior survival compared to those without a TP53 abnormality (PFS 70.0% vs 100%, p < 0.001, OS 78.0% vs 100%, p = 0.002). Moreover, amongst patients clinically defined as high-risk (stage III with high LDH or stage IV), those without a TP53 abnormality have superior survival compared to those with TP53 abnormalities (PFS 100% vs 55.6%, p = 0.005, OS 100% vs 66.7%, p = 0.019). Biallelic TP53 abnormalities were either maintained from the presentation or acquired at progression in all paired diagnosis/progression Burkitt lymphoma cases. TP53 abnormalities thus define clinical risk groups within paediatric B-NHL and offer a novel molecular risk stratifier, allowing more personalised treatment protocols.

Для цитирования: Newman Alexander M, Zaka Masood, Zhou Peixun, Blain Alex E, Erhorn Amy, Barnard Amy, Crossland Rachel E, Wilkinson Sarah, Enshaei Amir, De Zordi Julian, Harding Fiona, Taj Mary, Wood Katrina M, Televantou Despina, Turner Suzanne D, Burke G A Amos, Harrison Christine J, Bomken Simon, Bacon Chris M, Rand Vikki. Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma.. Leukemia. 2021. DOI: 10.1038/s41375-021-01444-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.